SASS6 promotes tumor proliferation and is associated with TP53 and immune infiltration in lung adenocarcinoma.

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical and Experimental Medicine Pub Date : 2024-10-24 DOI:10.1007/s10238-024-01510-0

Zihao Li, Lingyun He, Jiayi Li, Jing Qian, Zuotao Wu, Yongjie Zhu, Ting Zhuo, Jusen Nong, Honghua Liang, Hua Zheng, Weijia Huang, Julu Huang, Jianbin Cao

{"title":"SASS6 promotes tumor proliferation and is associated with TP53 and immune infiltration in lung adenocarcinoma.","authors":"Zihao Li, Lingyun He, Jiayi Li, Jing Qian, Zuotao Wu, Yongjie Zhu, Ting Zhuo, Jusen Nong, Honghua Liang, Hua Zheng, Weijia Huang, Julu Huang, Jianbin Cao","doi":"10.1007/s10238-024-01510-0","DOIUrl":null,"url":null,"abstract":"<p><p>The most common type of non-small cell lung cancer is lung adenocarcinoma (LUAD), which is characterized by high morbidity and poor survival. Up-regulation of SASS6 expression can lead to the progression of various malignant tumors. However, there are no relevant studies on the role of SASS6 in LUAD. SASS6 was highly expressed in most tumors, reflecting a good diagnostic value, and its overexpression in LUAD indicated discouraging overall prognosis. Functional enrichment analysis suggested that SASS6 was associated with cell cycle in LUAD. In addition, patients with high SASS6 expression had worse immune infiltration, but higher TMB and immune checkpoint, and higher sensitivity to multiple targeted drugs such as osimertinib. Cell experiments confirmed that knockdown of SASS6 could inhibit the viability of tumor cells.SASS6 has important value in the diagnosis of cancer. In particular, SASS6 is a crucial factor in the progression of LUAD, and has important clinical value, especially in the diagnosis, prognosis and treatment.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"24 1","pages":"243"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499408/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-024-01510-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

The most common type of non-small cell lung cancer is lung adenocarcinoma (LUAD), which is characterized by high morbidity and poor survival. Up-regulation of SASS6 expression can lead to the progression of various malignant tumors. However, there are no relevant studies on the role of SASS6 in LUAD. SASS6 was highly expressed in most tumors, reflecting a good diagnostic value, and its overexpression in LUAD indicated discouraging overall prognosis. Functional enrichment analysis suggested that SASS6 was associated with cell cycle in LUAD. In addition, patients with high SASS6 expression had worse immune infiltration, but higher TMB and immune checkpoint, and higher sensitivity to multiple targeted drugs such as osimertinib. Cell experiments confirmed that knockdown of SASS6 could inhibit the viability of tumor cells.SASS6 has important value in the diagnosis of cancer. In particular, SASS6 is a crucial factor in the progression of LUAD, and has important clinical value, especially in the diagnosis, prognosis and treatment.

查看原文本刊更多论文

SASS6 促进肿瘤增殖，与肺腺癌中的 TP53 和免疫浸润有关。

最常见的非小细胞肺癌类型是肺腺癌（LUAD），其特点是发病率高、生存率低。SASS6 表达的上调可导致各种恶性肿瘤的进展。然而，目前还没有关于 SASS6 在 LUAD 中作用的相关研究。SASS6在大多数肿瘤中高表达，具有良好的诊断价值，而在LUAD中的过表达则表明整体预后令人沮丧。功能富集分析表明，SASS6与LUAD的细胞周期有关。此外，SASS6高表达的患者免疫浸润较差，但TMB和免疫检查点较高，对奥希替尼等多种靶向药物的敏感性较高。细胞实验证实，敲除 SASS6 可抑制肿瘤细胞的活力。SASS6在癌症诊断中具有重要价值，尤其是SASS6是LUAD进展的关键因素，在诊断、预后和治疗方面具有重要的临床价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Medicine 医学-医学：研究与实验

CiteScore

4.80

自引率

2.20%

发文量

159

审稿时长

2.5 months

期刊介绍： Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.